Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on ...

compounds comprising a cereblon E3 ubiquitin ligase-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; ...

Betta Pharmaceuticals Co. Ltd. has prepared and tested probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors ...

Accelerated aging among survivors of childhood leukemia and lymphoma: Estimates of early onset and excess morbidity from the COMPASS model. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

FHD-286 is a highly potent, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases ...

Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation ...

Foghorn ® Therapeutics Inc. today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its ...

1 FHD-286 is a small molecule, enzymatic inhibitor of BRG1 and BRM. Preclinically, the agent has shown antitumor activity in multiple solid and hematologic malignancies. Data announced in a press ...

SMARCAL1 and BRG1, both classified as ATP-dependent chromatin remodeling proteins, play a role in double-strand break DNA damage response pathways. Mutations in SMARCAL1 cause Schimke Immuno-osseous ...